Fig. 7: Pharmacokinetic profiles of sunitinib MPs.

a C57BL/6 mice were given a 1 µl intravitreous injection of either MPs containing 1 µg sunitinib (closed bar) or an equivalent dose of sunitinib drug suspension (open bar) in both eyes. Immediately after injection or at 30 days after injection, 5 mice from each condition were euthanized, and the amount of sunitinib remaining in the eyes was evaluated by a validated extraction and the LC–MS method and presented as a percentage of the initial dose. b A 50 µl suspension of sunitinib MPs containing 1 mg sunitinib was administered to both eyes of pigmented New Zealand rabbits. After 500 μL of blood was collected, animals were euthanized and the eyes were enucleated immediately after sacrifice. Central region RPE-choroid, retina, and vitreous humor in one eye of each animal were collected for pharmacokinetic ocular tissue analysis at 24 h, Days 3 and 10, and Months 1–4, 6, and 7. N = 4 biologically independent samples for time points through 4 month, n = 2 for 6 months, and n = 1 for 7 months. c A 200 µl suspension of sunitinib MPs containing 2 mg sunitinib was administered to both eyes of pigmented New Zealand rabbits. Central region RPE-choroid and retina in one eye of each animal were collected Days 7 and 28 (n = 3 biologically independent samples for each tissue at each time point). Sunitinib levels in plasma and ocular tissues were evaluated by LC–MS. Source data are provided as a Source Data file.